Temperature-sensitive differential affinity of TRAIL for its receptors. DR5 is the highest affinity receptor - Wikidata - thesis-toulmin - TriplyDB

Temperature-sensitive differential affinity of TRAIL for its receptors. DR5 is the highest affinity receptor

Temperature-sensitive differential affinity of TRAIL for its receptors. DR5 is the highest affinity receptor

http://www.wikidata.org/entity/Q28142274

about

Irradiation specifically sensitises solid tumour cell lines to TRAIL mediated apoptosis Onto better TRAILs for cancer treatment Marine Drugs Regulating Apoptosis Induced by Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand (TRAIL)Getting TRAIL back on track for cancer therapy Crystal structure of TRAIL-DR5 complex identifies a critical role of the unique frame insertion in conferring recognition specificity Crystal structure of the TRANCE/RANKL cytokine reveals determinants of receptor-ligand specificity RANKL Employs Distinct Binding Modes to Engage RANK and the Osteoprotegerin Decoy Receptor Identification of a new murine tumor necrosis factor receptor locus that contains two novel murine receptors for tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)ABRF 2001: The new biology: Technologies for resolving macromolecular communications TNF superfamily: a growing saga of kidney injury modulators.Inducing apoptosis in rolling cancer cells: a combined therapy with aspirin and immobilized TRAIL and E-selectin The structure of the death receptor 4-TNF-related apoptosis-inducing ligand (DR4-TRAIL) complex.Blocking TRAIL-DR5 signaling with soluble DR5 alleviates acute kidney injury in a severely burned mouse model.Clinical significance of serum soluble death receptor 5 concentration in locally advanced non-small cell lung cancer patients.Preligand assembly domain-mediated ligand-independent association between TRAIL receptor 4 (TR4) and TR2 regulates TRAIL-induced apoptosis Mechanisms balancing skeletal matrix synthesis and degradation.Hepatocyte death: a clear and present danger.TRAIL in cancer therapy: present and future challenges.Structural basis of LaDR5, a novel agonistic anti-death receptor 5 (DR5) monoclonal antibody, to inhibit DR5/TRAIL complex formation The transmembrane domains of TNF-related apoptosis-inducing ligand (TRAIL) receptors 1 and 2 co-regulate apoptotic signaling capacity.TRAIL/Apo-2L: mechanisms and clinical applications in cancer.Rapid and efficient cancer cell killing mediated by high-affinity death receptor homotrimerizing TRAIL variants.Role of RANK ligand in mediating increased bone resorption in early postmenopausal women Osteoprotegerin expressed by osteoclasts: an autoregulator of osteoclastogenesis.The TRAIL to viral pathogenesis: the good, the bad and the ugly The Biology of TRAIL and the Role of TRAIL-Based Therapeutics in Infectious Diseases Increased bone mass in mice after single injection of anti-receptor activator of nuclear factor-kappaB ligand-neutralizing antibody: evidence for bone anabolic effect of parathyroid hormone in mice with few osteoclasts TRAIL and apoptosis induction by TNF-family death receptors.Zyflamend sensitizes tumor cells to TRAIL-induced apoptosis through up-regulation of death receptors and down-regulation of survival proteins: role of ROS-dependent CCAAT/enhancer-binding protein-homologous protein pathway.Expression of osteoprotegerin (OPG), TNF related apoptosis inducing ligand (TRAIL), and receptor activator of nuclear factor kappaB ligand (RANKL) in human breast tumours.Kinetics in signal transduction pathways involving promiscuous oligomerizing receptors can be determined by receptor specificity: apoptosis induction by TRAIL.Human agonistic TRAIL receptor antibodies Mapatumumab and Lexatumumab induce apoptosis in malignant mesothelioma and act synergistically with cisplatin.Increased serum TRAIL and DR5 levels correlated with lung function and inflammation in stable COPD patients.On the TRAIL of a new therapy for leukemia.Regulation of the extrinsic apoptotic pathway by the extracellular matrix glycoprotein EMILIN2.The TRAIL to targeted therapy of breast cancer.The TRAIL receptor agonist drozitumab targets basal B triple-negative breast cancer cells that express vimentin and Axl TRAIL, caspases and maturation of normal and leukemic myeloid precursors.The osteoprotegerin/RANK/RANKL system: a bone key to vascular disease.Human cytomegalovirus glycoprotein UL141 targets the TRAIL death receptors to thwart host innate antiviral defenses.

P2860

Q24798681-22C65E47-0A55-49F3-95A3-8DEDE571B66D Q26768160-97E93663-6D91-4CFB-A120-77C14583A7BD Q26859211-29C2283A-DCC3-4A54-B508-25917D89C607 Q27027460-9415B51C-305B-4EDD-B74F-32A3A02DDDDA Q27625357-9F7C6445-DED1-472B-98A6-D8F5EDA12548 Q27635130-87384051-A288-46C7-8147-BFCD372A9ECB Q27674275-F2996EA4-2DB4-4F9E-BD7B-3DFAA3EE20F1 Q28505264-3950C8BD-2B3E-439C-863F-4CD5DFA23F3D Q28755136-5D0C000C-8991-4D73-9190-657E8D3BEE5A Q30479123-5961E28E-B571-4A41-9740-B1D60DD8A55E Q30523992-2946584A-FE3E-40E8-91DD-21402C053EA9 Q31814863-17EA3B80-2364-49E5-8A5A-49CB79911A71 Q33898510-4A4412A5-F2DF-468C-8002-FC4D711CC985 Q33967735-EF12A0C7-222D-4757-86D4-71ACC45F324B Q33991741-3B150EFB-CC80-4AC3-841D-CF42413EFC76 Q34129759-DDC58F01-E515-4530-913E-1960A86A304D Q34147508-4BAF12C9-D088-4C20-9BFE-8C8ACBFFDA6A Q34291312-91A97E2C-06F5-4966-A254-71175A3BF226 Q34334395-FE8C84A7-380A-41CF-9656-B3A25ED3442B Q34390877-85777AE7-8C60-4506-961C-10240FBCE7F6 Q34482821-8AD0DE47-CBE7-4776-A1EB-BB22CF778FEC Q34561798-1B1C09F3-E767-4229-A490-BE896F821FB2 Q34912769-0E213A17-C6E6-440A-8181-05C860AC8F89 Q34950497-32DAD4B5-BFDB-4AF8-B74A-15D1982DE863 Q35146349-74DEC31A-9E9C-430D-91DD-62D6BD2AB8E2 Q35172090-4E5494B2-004B-4A30-97EC-C1993D751718 Q35378487-729EC29B-63FF-44DA-A75E-F375CE68E4D9 Q35591708-1C62B0A0-D175-4C1A-9850-14BAEB995274 Q35680133-5C65C217-B146-48D1-9E3D-963ABA43C0B3 Q35769514-08CF63E9-3AF7-41D2-BD1F-5433C32BF9E6 Q35863285-56179990-BFA4-4122-8A27-55C711D11C41 Q36259724-86D1931C-01D1-43D7-9CBE-AA42EB600404 Q36277943-844C8497-7C33-409D-9CCB-BD6BEF6FF1B3 Q36285964-DCB6736C-A7F4-4269-AECA-AEF64DC244B8 Q36315249-F28F9A0E-D8F0-47C7-8C8B-81A8621FB89F Q36511919-0836BF2B-64ED-4756-A4BF-708E31CD8926 Q36580632-A8326F71-004E-41D8-9355-4545D63EEF66 Q36590964-8460E358-FDE6-45CB-A211-926E8423A894 Q36686037-BA4F1229-760A-467E-9B6A-F68CF47D2C0D Q36695499-5846534E-69DE-499E-93C9-124AE2CCF78F

P2860

Temperature-sensitive differential affinity of TRAIL for its receptors. DR5 is the highest affinity receptor

http://www.wikidata.org/entity/Q28142274

description

2000 nî lūn-bûn

@nan

2000 թուականի Յուլիսին հրատարակուած գիտական յօդուած

@hyw

2000 թվականի հուլիսին հրատարակված գիտական հոդված

@hy

2000年の論文

@ja

2000年論文

@yue

2000年論文

@zh-hant

2000年論文

@zh-hk

2000年論文

@zh-mo

2000年論文

@zh-tw

2000年论文

@wuu

name

Temperature-sensitive differen ...... the highest affinity receptor

@ast

Temperature-sensitive differen ...... the highest affinity receptor

@en

Temperature-sensitive differen ...... the highest affinity receptor

@nl

type

label

Temperature-sensitive differen ...... the highest affinity receptor

@ast

Temperature-sensitive differen ...... the highest affinity receptor

@en

Temperature-sensitive differen ...... the highest affinity receptor

@nl

prefLabel

Temperature-sensitive differen ...... the highest affinity receptor

@ast

Temperature-sensitive differen ...... the highest affinity receptor

@en

Temperature-sensitive differen ...... the highest affinity receptor

@nl

P1433

Q28142274-4FCB5EA3-F66B-4AB1-9E67-77AD430EF8EA

P1476

Q28142274-660DE9DD-0E1A-475C-A516-27B16D94DF45

P2093

Q28142274-0965547F-0A6A-4897-BE87-8DD5E79781F7

Q28142274-2A0D2F7A-EB80-4A34-A469-5107AC787D64

Q28142274-2D3E30A0-61AD-47CA-AE7F-4F0049AF4FDC

Q28142274-2ED1AB43-BFD0-4608-A7EC-4D71DFBA480F

Q28142274-40746407-8860-440C-892B-D84E66E3CEB3

Q28142274-44FCCDC9-9F25-4C74-B0DE-706B02D6AA6D

Q28142274-7BE97E9A-6B48-4B00-88B8-EF31AB012869

Q28142274-7D58FB0D-D5C1-488F-AE4B-A69530582C91

Q28142274-A590DF31-60ED-41B6-A897-511171AA4D38

Q28142274-ACEABDE7-51E7-4D8B-A989-5F7319633C46

P304

Q28142274-A5506097-3F48-46CA-8683-7DD640510970

P31

Q28142274-6656ECB0-F5CF-4051-A229-0B0F87D2C514

P3181

Q28142274-DD26C1E1-5188-4517-B776-9830E1BEE0A5

P356

Q28142274-69B22333-D409-411A-8859-E14CDBC4C14C

P407

Q28142274-924F252F-57C3-412C-AD6D-3656F8BC713A

P433

Q28142274-7FEB05FB-8556-45C7-A446-DCA6276454FF

P478

Q28142274-49E8DB0A-3553-4DF9-90EC-6694182DDEA5

P577

Q28142274-0131725D-E028-4286-906D-16BBB6DFEF5B

P698

Q28142274-6D154EB6-833D-4802-997B-5DEC32959CAF

P3181

P356

P1433

Journal of Biological Chemistry

P1476

Temperature-sensitive differen ...... the highest affinity receptor

@en

P2093

A Truneh

http://www.w3.org/2001/XMLSchema#string

C Silverman

http://www.w3.org/2001/XMLSchema#string

E S Alnemri

http://www.w3.org/2001/XMLSchema#string

G P Livi

http://www.w3.org/2001/XMLSchema#string

K C Deen

http://www.w3.org/2001/XMLSchema#string

L A Marshall

http://www.w3.org/2001/XMLSchema#string

M L Doyle

http://www.w3.org/2001/XMLSchema#string

M M McLaughlin

http://www.w3.org/2001/XMLSchema#string

M P Reddy

http://www.w3.org/2001/XMLSchema#string

S Khandekar

http://www.w3.org/2001/XMLSchema#string

P304

23319-25

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

5102559

http://www.w3.org/2001/XMLSchema#string

P356

10.1074/JBC.M910438199

http://www.w3.org/2001/XMLSchema#string

P407

P433

30

http://www.w3.org/2001/XMLSchema#string

P478

275

http://www.w3.org/2001/XMLSchema#string

P577

2000-07-28T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

10770955

http://www.w3.org/2001/XMLSchema#string